Genomic profiling for defining luminal subtypes - European Medical Journal

Genomic profiling for defining luminal subtypes

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, explains the development of multigene tests, such as the Oncotype DX® Breast Cancer Assay and the PAM50 test, for classifying breast cancer into different subtypes. Luminal A and B subtypes of breast cancer may have important predictive value in the clinic.

This content is supported by Genomic Health, Inc.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given